ARCHIVES

Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent

This article is from The Cancer Letter archive.

Vol. 08 No. 02 | January 8, 1982

Download PDF Visit The Full Archive

Related Articles

Lung cancer screening trial reaches accrual goal of 50,000.

January 30, 2004

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

January 28, 2005

Major Emphasis Switch; Outreach Core Support Ends In Favor Of Cancer Control Research

January 22, 1982

First Lady Helps Dedicate New MDA Facilities

October 15, 1976

High Risk workshop Planned To Produce Monograph On Current Knowledge

October 11, 1974

Dingell To Challenge NCI, NSABP Handling Of Fraud, Delays

April 8, 1994